RxDoctor Payments Data

Omar Staples

Medical · Oakland, CANPI 1700931631

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 68 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$466
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • Collegium Pharmaceutical, Inc.$156
  • Novo Nordisk$107
  • Otsuka America Pharmaceutical, Inc.$86
  • Smith+Nephew$82
  • plus $350 from 11 others

What the payments were for

  • Food & beverage$1,31293%
  • Education$967%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,408 in reported general payments places this provider in the 70th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$665,618
Medicare patients
220
Services billed
3,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl18$44,492
EliquisApixaban40$22,021
OzempicSemaglutide19$19,544
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen880$16,761
Naloxone Hcl161$11,531
XareltoRivaroxaban12$10,075
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$9,935
EntrestoSacubitril/Valsartan12$8,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,178
Varenicline Tartrate21$5,614
Albuterol Sulfate HfaAlbuterol Sulfate160$4,619
Breo ElliptaFluticasone/Vilanterol12$4,382
Oxycodone Hcl141$4,162
Colchicine34$2,034
Ventolin HfaAlbuterol Sulfate36$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$22,02140 claims
Novo NordiskOzempic$107$19,54419 claims
Scilex Pharmaceuticals Inc.Colchicine$24$2,03434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 medical providers in California.

Other medical in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →